$0.78
Today
as of Aug 5, 16:50 ET
Last 30 days
Recent Press Releases & News
Standard BioTools: Q2 Earnings Snapshot
Standard BioTools Reports Second Quarter 2026 Financial Results
Standard BioTools Sells Mass Cytometry Business Amid Pending Merger With Treeline Biosciences
Overview
52-week range
$0.87
$1.72
0% of range
Avg surprise (last 3)
+13.9%
Avg reaction (last 2)
-1.8%
50% positive
Latest IV / EM
175%
EM ±33.4% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.03 | $-0.04 | +25.0% | +50.0% | +4.3% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.09 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.05 | $-0.06 | +16.7% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.06 | $-0.06 | 0.0% | — | -7.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.07 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.12 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.27 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.27 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.22 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $11M | — | $9M | $11M | $11M | — | $12M | $10M |
| Operating income | $-12M | — | $-33M | $-26M | $-27M | — | $-27M | $-30M |
| Net income | $127M | — | $-35M | $-33M | $-26M | — | $-27M | $-46M |
| EPS (diluted) | $0.33 | — | $-0.09 | $-0.09 | $-0.07 | — | $-0.07 | $-0.12 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $266M | $121M | $129M | $159M | $151M | $167M | $211M | $270M |
| Inventory | $19M | $20M | $25M | $24M | $42M | $21M | $43M | $43M |
| Total current assets | $521M | $454M | $472M | $506M | $344M | $376M | $454M | $480M |
| Total assets | $639M | $568M | $540M | $557M | $580M | $612M | $682M | $709M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $78M | $143M | $140M | $132M | $125M | $141M | $192M | $198M |
| Total equity | $561M | $424M | $400M | $425M | $455M | $472M | $489M | $510M |